PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of iranjphealthThis JournalSearchAuthor GuidelinesAim and ScopeSubmit a ManuscriptIJPHTUMS
 
Iran J Public Health. 2017 February; 46(2): 235–241.
PMCID: PMC5402783

Caspofungin-Non-Susceptible Candida orthopsilosis Isolated from Onychomycosis in Iran

Abstract

Background:

Although Candida albicans remains the most common fungal isolate from clinical specimens, many studies have detected a shift towards non-albicans Candida species. Despite worrying clinical pictures associated with latter species, there is little information regarding its susceptibility patterns against currently available antifungal agents, with only a small number of strains having been studied.

Methods:

We evaluated the in vitro antifungal susceptibilities of clinical isolates of C. orthopsilosis already identified by two-steps PCR-RFLP and reconfirmed by sequence analysis of entire ITS rDNA region, to six antifungal drugs.

Results:

The resulting MIC50 and MIC90 for all strains (n=18) were in increasing order, as follows: posaconazole (0.016 & 0.063 μg/ml); itraconazole (0.031 & 0.125 μg/ml); amphotericin B (0.5 & 1 μg/ml); fluconazole (0.25 & 0.5 μg/ml) and caspofungin (4 & 8 μg/ml). A uniform pattern of the MIC ranges was seen for amphotericin B, fluconazole, itraconazole, and posaconazole, while a widest range and the highest MICs were observed for caspofungin.

Conclusion:

Although we emphasis on the careful species designation of the clinical isolates of Candida, the antifungal susceptibility patterns of these clinically important organisms may have an application in clinical and epidemiological setting and deserve the implementation of local surveillance programs to monitor.

Keywords: Candida orthopsilosis, Onychomycosis, Antifungal susceptibility, Iran

Introduction

Candida albicans has been considered the main cause of Candida infections, but non-albicans Candida species, such as C. glabrata, C. tropicalis, C. parapsilosis complex, and C. krusei are also significant pathogens (1, 2). Considering the variable antifungal susceptibility profiles of different Candida species and the emergence of diseases due to rare Candida species, correct species delineation is necessary for clinicians to make a well-documented therapeutic decision (36). Candida parapsilosis was a complex of three genetic groups designated as I, II and III. This classification was based on several molecular studies and according to the results from various approaches. Subsequently according to a multilocus sequence typing scheme, C. parapsilosis groups I, II and III should be reclassified as the species C. parapsilosis, C. orthopsilosis and C. metapsilosis, respectively (4). Among the most common Candida species involved in invasive candidiasis, C. parapsilosis sensu lato is particularly common in neonates, in catheter-associated candidaemia and in association with intravenous hyper alimentation, as well as in superficial candidiasis such as onychomycosis (7, 8).

A small proportion of some isolates are actually the closely related species C. orthopsilosis or C. metapsilosis, with a significant geographical variation (4, 9). Although, C. parapsilosis group is normally susceptible to most antifungal compounds, elevated MICs for the echinocandin agents are consistently reported for this species, probably due to an intrinsic mutation in the FKS hot spot (10). An echinocandin MIC of >8 μg/ml is used to identify caspofungin-resistant C. parapsilosis and susceptibility differences within the C. parapsilosis group could affect therapeutic choices (11). Unfortunately, CLSI clinical breakpoint (CBP) values for C. orthopsilosis is unclear. Recently we reported the species distribution of several hundred clinical isolates of yeasts, obtained from four different provinces in Iran. A set of polymerase chain reaction (PCR) amplification of ITS1-5.8S-ITS2 region of rDNA and secondary alcohol dehydrogenase (SADH) gene, followed by restriction fragment length polymorphism (RFLP) for each targets was used for species delineation of the isolates. In this study, C. parapsilosis complex were the second most common (after C. albicans) isolates and the most abundant of non-albicans Candida isolates. Overall, 128 strains of C. parapsilosis group including 110 C. parapsilosis sensu stricto and 18 C. orthopsilosis were isolated from different kinds of clinical samples mostly from nails scrapings.

In the present study we focused on the C. orthopsilosis strains. The identity of these isolates was reconfirmed by ITS rDNA-sequencing and their in vitro antifungal susceptibility profile was conducted for several antifungal drugs.

Materials and Methods

All C. orthopsilosis strains used in this study were screened from several hundred clinical yeast isolates, which already delineated to the species level among 2009 to 2011 from patients with various clinical forms of candidiasis (8). C. orthopsilosis were screened as described previously (12). Furthermore to confirm the species recognized as C. orthopsilosis, a total of five ITS-PCR products relevant to five C. orthopsilosis strains, were randomly selected and subjected to identifying by sequencing the ITS1-5.8S-ITS2 region with the universal primers ITS1 and ITS4 (13). Sequencing was performed by using an ABI 3730XL automatic sequencer (Applied Biosystems, Foster City, CA, U.S.A.). The consensus edited sequences were subjected to nucleotide BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and DNASIS multiple alignment analysis.

In vitro antifungal susceptibility testing

Minimum inhibitory concentration (MICs) was determined according to recommendations stated in the clinical and laboratory standards institute (CLSI) M27-A3 and M27-S4 documents (14, 15). Amphotericin B (Bristol-Myers-Squib, Woerden, and the Netherlands), fluconazole (Pfizer Central Research, Sandwich, United Kingdom), itraconazole (Janssen Research Foundation, Beerse, Belgium), posaconazole (Schering-Plough, Kenilworth, USA) and caspofungin (Merck Sharp & Dohme, Haarlem, The Netherlands) were used for preparation of the CLSI microdilution trays. The antifungal agents were diluted in the standard RPMI-1640 medium (Sigma Chemical Co.) buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS) (Sigma) with L-glutamine without bicarbonate. To yield two times concentrations and dispensed into 96-well microdilution trays at a final concentration of 0.016–16 μg/ml for amphotericin B, itraconazole, posaconazole; 0.063–64 μg/ml for fluconazole and 0.08–8 μg/ml for caspofungin. Plates were stored at −70 °C until use. All identified C. orthopsilosis were grown on malt extract agar (MEA, Difco) plates at 35 °C and inoculum suspensions were prepared by harvesting the cell from 24 h old cultures and were adjusted spectrophotometrically in saline to optical densities ranged 75–77% transmission. Final inoculum sizes ranged from 2.5×103 to 5×103 CFU/ml as demonstrated by a quantitative colony count on Sabouraud’s dextrose agar. MIC results for all agents were read following 24 h of incubation at 35 °C. MIC values were determined visually, as the lowest concentration of drug that caused complete (amphotericin B) or significant (>50%) growth diminution levels (all other agents) (14). C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 were chosen as quality controls to be used with every new series of MICs plates. Based on newly revised CLSI clinical breakpoint (CBP) for caspofungin MIC values of <0.12 and >0.5 μg/ml were considered susceptible and resistant, respectively. For C. glabrata; fluconazole MIC results of <2 and >8 μg/ml were defined as susceptible and resistant, respectively. For C. albicans, C. parapsilosis, and C. tropicalis, and MICs of <32 and >64 μg/ml were considered susceptible dose dependent (SDD) and resistant, respectively. For C. glabrata susceptible and resistant breakpoints for voriconazole are <0.12 and >1 μg/ml, respectively. For C. albicans, C. parapsilosis, and C. tropicalis, CLSI has not assigned CBPs for voriconazole and C. glabrata and recommends the ECV of 0.5 μg/ml to be used to differentiate wild type (WT; MIC < ECV) from non-WT (MIC>ECV) strains of this species (15, 16).

Statistical Analysis

The MIC range, geometric, MIC50 and MIC90 were performed. The MIC50 and MIC90 values were calculated as the minimum concentrations of agents that were able to inhibit 50% and 90% of the isolates, respectively. The high and low off-scale MICs were included in the analysis by conversion to the next higher and lower antifungal concentrations, based on CLSI breakpoint (1416). Data were analyzed using the SPSS software ver. 14.0 (Chicago, IL, USA). Comparison of species distribution and antifungal susceptibility rates was adjusted using Fisher’s exact test and Mann-Whitney U-test. A P-value of < 0.05 was considered significant.

Results

Among 128 isolates genetically identified as C. parapsilosis sensu stricto, 18 strains were recognized to be C. orthopsilosis (Table 1). The remaining was C. parapsilosis sensu stricto but no C. metapsilosis was found. Five isolates were randomly selected for ITS rDNA sequence analysis. The results confirmed the species that recognized by PCR-RFLP (Fig. 1).

Fig. 1:
Digestion of SADH-PCR products with NlaIII restriction enzyme in the group of C. parapsilosis Lane 1, 2, 3, 4, 5, 7: C. parapsilosis, and lanes 6 and 8: C. orthopsilosis
Table 1:
Species distribution of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis evaluated in this study

The sequences were deposited in GenBank with the accession numbers JQ366004-JQ366008. Table 2 summarized the in vitro antifungal susceptibility testing of the C. orthopsilosis isolates.

Table 2:
In vitro susceptibilities of 18 clinical isolates of C. orthopsilosis to five antifungal agents

A uniform pattern of the MIC ranges were seen for amphotericin B (0.25–2 μg/ml), fluconazole (0.25–2 μg/ml), itraconazole (0.016–0.25 μg/ml) and posaconazole (0.002–0.063 μg/ml), while a widest range (1–8 μg/ml) and the highest MICs (8 μg/ml) were observed for caspofungin. In terms of MIC50 (0.016 μg/ml), and MIC90 (0.063μg/ml) posaconazole was more active than both fluconazole (MIC50 0.25 and MIC90 0.5 μg/ml) and itraconazole (MIC50 0.031 and MIC90 0.125 μg/ml). Fluconazole exhibited the potent activity against C. orthopsilosis and fluconazole resistance (MIC > 8 μg/ml) and susceptible dose dependent (SDD) (4 μg/ml) were not observed among the isolates. In terms of MIC50 and MIC90 caspofungin (4 and 8 μg/ml) was higher than other antifungal agents and all isolates were highly resistant to caspofungin.

Discussion

Molecular screening of 128 C. parapsilosis strains isolated from clinical sources (mainly from nail) in Iran revealed that 14% of infections are ascribed to C. orthopsilosis. In accordance with the present study, C. metapsilosis has been infrequently recovered from clinical samples (17, 18), while C. orthopsilosis was recovered from blood, nails, skin, lungs, urine, and catheters (19). The higher prevalence of C. parapsilosis may be related to its ubiquitous nature, since it is commonly isolated from different environmental sources or might be related to larger virulence factors compared to two other relative species (12). However, this still needs to be entirely confirmed. Interestingly, prevalence of C. orthopsilosis is very high in comparison with the same studies in other countries. For instance, only one C. orthopsilosis isolate without any C. metapsilosis was reported (20). Any C. orthopsilosis found among the isolates (21). Thirteen out of 240 isolates (4.5%) were revealed of C. orthopsilosis isolates without any C. metapsilosis (19), any C. orthopsilosis found among 395 isolates but reported 20 (5.1%) strains of C. metapsilosis (22). Higher frequency of C. orthopsilosis was reported, 28.1% C. orthopsilosis isolates (4) and 24.4% in comparison with our survey (14%) (23). The prevalence and distribution of the species in the C. orthopsilosis caused candidiasis is not yet clear. However, we found that at least a significant number of C. orthopsilosis could be from superficial lesions as reported in other studies (19, 2426). DNA-based methods provide data that are more accurate and reproducible than visual characteristics and phenotypic properties. In addition, by given the expansion of non-Candida albicans yeast infections, and the distinct antifungal susceptibility profile of the related species, accurate and precise identification becomes essential for clinical management of the patients.

In vitro antifungal susceptibility of C. orthopsilosis against fluconazole showed similar susceptibility profiles in comparison to the results (16, 25). The high MICs to caspofungin of C. orthopsilosis isolates in our study agree to the previous findings (18, 25). However, few studies showed limited evidence of resistance to caspofungin against clinical isolates of C. orthopsilosis (2830). An MIC of caspofungin of >4 μg/ml only in 6 (0.1%) of 5346 isolates tested without any evidence of increasing caspofungin resistance over the last 6 yr of their study (31). In our study, an MIC of caspofungin based on both recently revised CLSI clinical breakpoint value and old clinical breakpoint value (14) of >8 μg/ml was observed in four isolates tested. In terms of MIC50 and MIC90 patterns obtained in the current study suggested that C. orthopsilosis is resistant to caspofungin. Although limited by small numbers, this study provides additional information of resistant C. orthopsilosis obtained from onychomycosis. However, their clinical effectiveness in the treatment of C. orthopsilosis infections remains to be determined.

Conclusion

We emphasis on the careful species designation of the clinical isolates of Candida, specially Candida metapsilosis and C. orthopsilosis as cryptic species from C. parapsilosis with different prevalence rates, virulence and in vitro susceptibility profiles. Although clinical resistance to azoles has been increasingly reported in C. parapsilosis, in the current study, all tested C. orthopsilosis isolates were found to be susceptible to fluconazole and non-susceptible to caspofungin. It seems that with increasing usage of echinocandins, the epidemiology and resistance distribution of C. orthopsilosis deserve attention.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgments

This study was financially supported by a grant from the School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran, which we gratefully acknowledge. The authors declare that there is no conflict of interest.

References

1. Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS. (2013). Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol, 62(Pt 1):10–24. [PubMed]
2. Afsarian SM, Badali H, Shokohi T, Najafipour S. (2015). Molecular Diversity of Candida albicans Isolated from Immunocompromised Patients, Based on MLST Method. Iran J Public Health, 44(9):1262–9. [PMC free article] [PubMed]
3. Sandven P. (2000). Epidemiology of candidemia. Rev Iberoam Micol, 17:73–81. [PubMed]
4. Tavanti A, Davidson AD, Gow NAR, Maiden MCJ, Odds FC. (2005). Candida orthopsilosis and Candida metapsilosis spp. nov. to Replace Candida parapsilosis Groups II and III. J Clin Microbiol, 43(1):284–92. [PMC free article] [PubMed]
5. Pfaller MA, Jones RN, Doern GV, et al. (2000). Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997–1998. Antimicrob Agents Chemother, 44 (3):747–51. [PMC free article] [PubMed]
6. Pfaller MA, Diekema DJ. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin Microbiol Rev, 20 (1):133–63. [PMC free article] [PubMed]
7. Fesharaki SH, Haghani I, Mousavi B, et al. (2013). Endocarditis due to a co-infection of Candida albicans and Candida tropicalis in a drug abuser. J Med Microbiol, 62(Pt 11):1763–7. [PubMed]
8. Mohammadi R, Mirhendi H, Rezaei-Matehkolaei A, et al. (2013). Molecular identification and distribution profile of Candida species isolated from Iranian patients. Med Mycol, 51(6):657–63. [PubMed]
9. Gonçalves SS, Amorim CS, Nucci M, et al. (2010). Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. Clin Microbiol Infect, 16 (7):885–7. [PubMed]
10. Garcia-Effron G, Park S, Perlin DS. (2009). Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother, 53 (1):112–22. [PMC free article] [PubMed]
11. Van Asbeck E, Clemons KV, Martinez M, Tong AJ, Stevens DA. (2008). Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis, 62 (1):106–9. [PubMed]
12. Mirhendi H, Bruun B, Schønheyder HC, et al. (2010). Molecular screening for Candida orthopsilosis and Candida metapsilosis among Danish Candida parapsilosis group blood culture isolates: proposal of a new RFLP profile for differentiation. J Med Microbiol, 59 (Pt 4):414–20. [PubMed]
13. Yazdanparast SA, Khodavaisy S, Fakhim H, et al. (2015). Molecular Characterization of Highly Susceptible Candida africana from Vulvovaginal Candidiasis. Mycopathologia. 180(5–6):317–23. [PubMed]
14. CLSI. M27-A3 Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed Wayne, PA: Clinical and Laboratory Standards Institute; 2008
15. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts: fourth informational supplement M27-S4. (2012). CLSI, Wayne, PA, USA.
16. Pfaller MA, Diekema DJ. (2012). Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, to 2012. J Clin Microbiol, 50(9):2846–56. [PMC free article] [PubMed]
17. Mohammadi R, Badiee P, Badali H, et al. (2015). Use of restriction fragment length polymorphism to identify Candida species, related to onychomycosis. Adv Biomed Res, 4:95. [PMC free article] [PubMed]
18. Silva AP, Miranda IM, Lisboa C, Pina-Vaz C, Rodrigues AG. (2009). Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol, 47 (8):2392–97. [PMC free article] [PubMed]
19. Tavanti A, Hensgens LAM, Ghelardi E, Campa M, Senesi S. (2007). Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J Clin Microbiol, 45 (5):1455–62. [PMC free article] [PubMed]
20. Pryce TM, Palladino S, Price DM, et al. (2006). Rapid identification of fungal pathogens in BacT/ALERT, BACTEC, and BBL MGIT media using polymerase chain reaction and DNA sequencing of the internal transcribed spacer regions. Diagn Microbiol Infect Dis, 54 (4):289–97. [PubMed]
21. Kocsubé S, Tóth M, Vágvölgyi C, et al. (2007). Occurrence and genetic variability of Candida parapsilosis sensu lato in Hungary. J Med Microbiol, 56 (Pt 2):190–5. [PubMed]
22. Hensgens LA, Tavanti A, Mogavero S, Ghelardi E, Senesi S. (2009). AFLP genotyping of Candida metapsilosis clinical isolates: evidence for recombination. Fungal Genet Biol, 46 (10):750–8. [PubMed]
23. Tay ST, Na SL, Chong J. (2009). Molecular differentiation and antifungal susceptibilities of Candida parapsilosis isolated from patients with bloodstream infections. J Med Microbiol, 58 (Pt 2):185–91. [PubMed]
24. de Toro M, Torres MJ, Maite R, Aznar J. (2011). Characterization of Candida parapsilosis complex isolates. Clin Microbiol Infect, 17 (3):418–24. [PubMed]
25. Treviño-Rangel RJ, Garza-González E, González JG, Bocanegra-García V, Llaca JM, González GM. (2012). Molecular characterization and antifungal susceptibility of the Candida parapsilosis species complex of clinical isolates from Monterrey, Mexico. Med Mycol, 50 (7):781–4. [PubMed]
26. Feng X, Ling B, Yang G, Yu X, Ren D, Yao Z. (2012). Prevalence and distribution profiles of Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis responsible for superficial candidiasis in a Chinese university hospital. Mycopathologia, 173 (4):229–34. [PubMed]
27. Cantón E, Espinel-Ingroff A, Pemán J, del Castillo L. (2010). In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother, 54 (5): 2194–97. [PMC free article] [PubMed]
28. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. (2006). In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol, 44 (3):760–3. [PMC free article] [PubMed]
29. Sanguinetti M, Posteraro P, Posteraro B. (2010). Echinocandin antifungal drug resistance in Candida species: a cause for concern? Curr Infect Dis Rep, 12 (6):437–43. [PubMed]
30. Fakhim H, Emami S, Vaezi A, Hashemi SM, Faeli L, Diba K, Dannaoui E, Badali H. (2017). In Vitro Activities of Novel Azole Compounds (ATTAF-1 and ATTAF-2) Against Fluconazole-Susceptible and - Resistant Isolates of Candida species. Antimicrob Agents Chemother, 61 (1); e01106–16. [PMC free article] [PubMed]
31. Pfaller MA, Boyken L, Hollis RJ, et al. (2008). In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol, 46 (1):150–6. [PMC free article] [PubMed]

Articles from Iranian Journal of Public Health are provided here courtesy of Tehran University of Medical Sciences